Psoriasis is a skin disease where various cytokines play a detrimental role, yet our
understanding of the disease is still limited. TNF is a validated drug target in psoriasis and …

Background In patients with various autoimmune and rheumatic diseases, a drug‐induced
lupus‐like syndrome (DILS) has been reported with the use of adalimumab, cerrolizumab …

Objective To describe the clinical characteristics, histopathologic features, and outcomes of
patients in whom vasculitis developed in association with use of tumor necrosis factor-α …

Objectives: The broader and prolonged use of anti-tumor necrosis factor (TNF) agents in
inflammatory bowel disease (IBD) could expose patients to an increased risk of adverse …

Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is
approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate …

Anti-tumour necrosis factor (TNF)-α agents have been increasingly used to treat patients
affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory …

Background: Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor
necrosis factor (TNF)-α therapy have been reported more frequently in recent years, but data …

Cell therapy is one of the methods that have shown promising results in treating diseases in
recent decades. However, the use of different types of cells comes with limitations. The …

Background: An increased risk of autoimmune disease has been reported in patients with
inflammatory bowel disease [IBD]. Using data from the Clinical Practice Research Datalink …

Targeted biologic agents have dramatically changed the therapeutic landscape for immune-
mediated inflammatory diseases, particularly in rheumatology and dermatology. Their …